Results 221 to 230 of about 355,585 (385)

Anticoagulant update [PDF]

British Dental Journal, 2013
openaire   +2 more sources

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

The association of anticoagulant use and hospitalization for hemorrhagic stroke among older adults aged 75 or older: A propensity score-matched study. [PDF]

Aging Clin Exp Res
Mitsutake S, Ono K, Akishita M, Hirata T.   +3 more
europepmc   +1 more source

Erratum to “Non-vitamin K antagonist oral anticoagulant reversal: hope is on the horizon” [The American Journal of Surgery 212 (1) 160-164] [PDF]

, 2016
Brian K. Yorkgitis
openalex   +1 more source

MANAGEMENT OF TOOTH EXTRACTIONS IN PATIENTS RECEIVING THE NEW ORAL ANTICOAGULANTS

, 2022
Lyudmila Vladimirova‐Kitova, Atanaska Dinkova, C. Daskalov, S. Kitov   +3 more
openalex   +1 more source

Anticoagulants for Strokes [PDF]

BMJ, 1964
openaire   +2 more sources

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Impact of Anticoagulation Therapy on Healthcare Utilization in Patients With Epistaxis. [PDF]

Laryngoscope Investig Otolaryngol
Andersen B, Kadrie A, Chanamolu M, Gillespie MB.   +3 more
europepmc   +1 more source

115Anticoagulation in atrial fibrillation – a single-centre audit on patient education, stroke and bleeding risk assessments and use of direct oral anticoagulants (DOACs) [PDF]

, 2017
SM Ng, Belén San José, Abhishek Sethi
openalex   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source